← ALL PUBLICATIONS

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML

May 2025

AUTHORS

Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones, Anurag K. Singh, Mark R. Litzow, John R. Wingard, Esperanza B. Papadopoulos, Alexander E. Perl, Robert J. Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L. Uy, Edmund K. Waller, Sumithira Vasu, Melhem Solh, Asmita Mishra, Lori S. Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H. Wei, Guido Marcucci, Caroline Chen, Nahla Hasabou, Matt Rosales, Jason Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Adam Mendizabal, Steven M. Devine, Mary M. Horowitz, Yi-Bin Chen